Treatment Trials

5 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
      Description

      This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.

      Conditions
      Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
      Talk to us
      RECRUITING
      The Evaluation of PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
      Description

      The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

      Conditions
      Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic CancerMetastatic Solid TumorLung CancerOvarian CancerEndometrial CancerProstate CancerColorectal CancerBreast CancerOther CancerLocally AdvancedHead and Neck CancerGall Bladder CancerSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )Small Cell Lung CarcinomaNSCLCNSCLC (non-small Cell Lung Cancer)SCLCNon-Small Cell Lung CarcinomaTriple Negative Breast CancerTNBCHER2+ Breast CancerNon-Small Cell Lung CancerER/PR Positive Breast CancerHER2- Breast CancerHER2-positive Breast CancerHER2-negative Breast CancerER/PR(+), Her2(-) Breast Cancer
      Talk to us
      COMPLETED
      A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
      Description

      The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion (triple negative breast cancer \[TNBC\] cohort and head and neck cancer cohort) and 18F-AraG Imaging Substudy.

      Conditions
      Advanced Solid Tumors Cancer
      Talk to us
      NOT_YET_RECRUITING
      A Long-Term Follow-Up Study of Participants Treated with A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
      Description

      This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

      Conditions
      Solid Tumor CancerSolid Tumor, Unspecified, AdultColorectal CarcinomaColorectal Carcinoma (CRC)Non Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )Pancreatic CancerNSCLCMesotheliomaOvarian CancerOvarian CarcinomaHead and Neck (HNSCC)Head and Neck CancerRenal Cell Carcinoma (Kidney Cancer)Triple Negative Breast Cancer (TNBC)
      Talk to us
      TERMINATED
      INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
      Description

      The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.

      Conditions
      Advanced MalignanciesMetastatic Cancer
      Talk to us